Irritable Bowel Syndrome
Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint
Clinical Pathway
Irritable Bowel Syndrome (IBS) is a common, chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits, without any identifiable structural or biochemical abnormalities. Management involves a combination of dietary modifications, lifestyle changes, and pharmacotherapy tailored to the predominant symptoms. Dietary approaches like the low-FODMAP diet, stress management techniques, and regular exercise are often recommended. Medications include antispasmodics for pain, laxatives for constipation, anti-diarrheals, and sometimes low-dose tricyclic antidepressants or selective serotonin reuptake inhibitors to modulate pain and gut function. Psychological therapies such as cognitive behavioral therapy (CBT) are also effective. Key symptoms include recurrent abdominal pain, often cramping, which is related to defecation or a change in stool frequency or form. Patients experience altered bowel habits, presenting as predominant diarrhea (IBS-D), constipation (IBS-C), or a mixed pattern (IBS-M). Other common symptoms include bloating, gas, abdominal distension, and a sense of incomplete evacuation.
Clinical Reasoning
IBS is a multifactorial disorder involving altered gut motility, visceral hypersensitivity, and dysfunction of the brain-gut axis. Contributing factors include dysregulation of the gut microbiome, post-infectious inflammation, and psychological stressors, which collectively lead to increased gut permeability and immune activation. There are no structural changes in the bowel; rather, it's a functional disturbance in the communication between the gut and the brain. IBS is a chronic condition with a fluctuating course, characterized by periods of symptom exacerbation and remission. While it significantly impacts quality of life, it does not lead to serious organic diseases, increase the risk of inflammatory bowel disease, or predispose to colorectal cancer. With appropriate management, most individuals can achieve significant symptom control and maintain a good quality of life. Female sex,Younger age (typically under 50),History of gastroenteritis (post-infectious IBS),Family history of IBS,Presence of psychological stressors, anxiety, or depression,History of stressful or traumatic life events
Sample MCQ
A 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) reports persistent abdominal pain, bloating, and urgent bowel movements despite trials of dietary modifications, loperamide, and dicyclomine. Her physician plans to initiate a 5-HT3 receptor antagonist approved for refractory IBS-D in women to decrease visceral hypersensitivity and colonic motility. Which medication is the most appropriate choice?
- ADiphenoxylate
- BDicyclomine
- CLoperamide
- DAlosetron
Correct Answer: D
### TLDR The patient's presentation of severe, refractory IBS-D in a woman, requiring a 5-HT3 receptor antagonist to reduce visceral hypersensitivity and colonic motility, points directly to **Alosetron**. This drug is specifically indicated for such cases after conventional therapies have failed. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :------- | :-------------------------------- | :------------------------------ | :---------------------------------- | | Diphenoxylate | Opioid agonist; slows gut motility. | Diarrhea treatment, often with atropine. | Opioid, abuse potential, not 5-HT3. | | Dicyclomine | Anticholinergic, antispasmodic. | Reduces abdominal pain/spasms in IBS. | Smooth muscle relaxant, not 5-HT3. | | Loperamide | Peripheral mu-opioid agonist; slows gut. | Symptomatic relief for diarrhea. | Conventional anti-diarrheal, not 5-HT3. | | **Alosetron** | 5-HT3 receptor antagonist. | Severe IBS-D in women, refractory cases. | Specific 5-HT3 action, targets visceral pain. | ### Detailed Breakdown The question describes a 45-year-old female with severe diarrhea-predominant irritable bowel syndrome (IBS-D) that has been refractory to conventional treatments like dietary modifications, loperamide, and dicyclomine. The key to identifying the correct drug lies in its specified mechanism of action: a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist, specifically approved for women with severe IBS-D who have not responded to conventional therapy, to reduce visceral hypersensitivity and colonic motility. **Alosetron** is precisely this drug. It is a selective 5-HT3 receptor antagonist that reduces visceral pain sensation, slows colonic transit time, and decreases colonic motility, which are beneficial effects in IBS-D. Due to its potential for serious adverse effects, including ischemic colitis, its use is restricted to women with severe IBS-D who have not responded to conventional therapy and meet specific criteria. This perfectly aligns with the clinical scenario presented. Let's look at why the other options are incorrect: * **Diphenoxylate** is an opioid agonist that reduces gut motility. It is used for diarrhea but is not a 5-HT3 antagonist and is not specifically indicated for severe refractory IBS-D with the described mechanism of action. It also has a potential for abuse, often formulated with atropine. * **Dicyclomine** is an anticholinergic and antispasmodic agent used to relieve abdominal pain and cramping in IBS. The patient in the scenario has already failed a trial of dicyclomine, and it is not a 5-HT3 antagonist. * **Loperamide** is a peripheral mu-opioid receptor agonist that slows intestinal motility and reduces fluid and electrolyte loss. It is a common over-the-counter medication for diarrhea but is not a 5-HT3 antagonist. Moreover, the patient has already failed loperamide treatment, indicating a need for a different mechanism of action. Therefore, given the specific mechanism of action (5-HT3 receptor antagonist) and the indication (severe, refractory IBS-D in women), **Alosetron** is the only correct answer.
Related Clinical Topics
AIDS
AIDS (Acquired Immunodeficiency Syndrome) is the final, most severe stage of HIV infection, characterized by a profoundly compromised immune system that makes individuals highly susceptible to opportunistic infections and certain cancers. It is diagnosed when the CD4+ T-cell count drops below 200 cells/mm³ or when specific AIDS-defining opportunistic illnesses develop. The cornerstone of AIDS treatment is highly active antiretroviral therapy (HAART), a combination of drugs that suppress HIV replication, preserve immune function, and prevent further progression. HAART significantly reduces viral load, increases CD4+ T-cell counts, and improves overall health. Treatment also includes prophylactic antibiotics to prevent opportunistic infections and specific therapies for any active infections or cancers. Symptoms of AIDS are primarily due to the opportunistic infections and cancers that take advantage of the severely weakened immune system. Common manifestations include persistent fever, chronic diarrhea, significant unintentional weight loss, night sweats, fatigue, swollen lymph nodes, and recurrent severe infections like Pneumocystis pneumonia, Kaposi's sarcoma, and toxoplasmosis. Neurological complications such as AIDS dementia complex can also occur.
Bradycardia
Bradycardia is a medical condition characterized by a slower than normal heart rate, typically defined as fewer than 60 beats per minute (bpm) in adults. While sometimes physiological and benign, it can also indicate underlying cardiovascular or systemic issues that impair the heart's ability to effectively pump blood. Treatment for bradycardia depends on its underlying cause, severity, and the presence of symptoms. Asymptomatic bradycardia, especially in athletes, often requires no intervention. Symptomatic bradycardia may necessitate discontinuing or adjusting causative medications, treating underlying conditions, or in severe cases, implanting a permanent pacemaker to regulate heart rhythm. Acute, unstable bradycardia may require intravenous atropine or temporary pacing. Clinical manifestations range from asymptomatic presentation to severe symptoms depending on the degree of bradycardia and the patient's cardiovascular reserve. Common symptoms include fatigue, dizziness, lightheadedness, syncope (fainting), shortness of breath, and chest pain. In critical cases, it can lead to confusion, hypotension, and signs of organ hypoperfusion.
Chronic Hepatitis C Virus infection
Chronic Hepatitis C Virus (HCV) infection is a persistent inflammatory condition of the liver caused by the hepatitis C virus, defined by the presence of detectable HCV RNA for at least six months. This long-term infection can progressively lead to significant liver damage, including fibrosis, cirrhosis, and hepatocellular carcinoma. Current treatment primarily involves direct-acting antiviral (DAA) medications, which are highly effective oral regimens targeting specific viral proteins to inhibit HCV replication. These therapies typically achieve a sustained virologic response (SVR) in over 95% of patients, effectively curing the infection. Treatment duration usually ranges from 8 to 12 weeks, depending on the specific regimen and patient factors. Chronic HCV infection is often asymptomatic for many years, leading to a silent progression of liver disease. When symptoms do appear, they are often non-specific, such as fatigue, malaise, nausea, and right upper quadrant discomfort. As the disease advances to cirrhosis, signs of liver decompensation may emerge, including jaundice, ascites, peripheral edema, spider angiomata, and hepatic encephalopathy.
SMLE Preparation Resources
Master the 2026 SMLE
Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.
Try the QBank & Scaled Mocks